Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly tafenoquine for malaria prophylaxis in Vietnamese peacekeeping personnel
ACTRN12622000272796Phase 4Withdrawn
- Sponsor
- Australian Defence Force Malaria and Infectious Disease Institute
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafenoquine in malaria, sponsored by Australian Defence Force Malaria and Infectious Disease Institute. Primary endpoints: Safety of weekly tafenoquine, Tolerability of weekly tafenoquine and 1 more. Planned start Mar 2022; status: withdrawn.
02
Drugs
tafenoquine
03
Conditions
malaria
Beyond the preview
Go deeper on ACTRN12622000272796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000272796.